Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbisko, Abelzeta, Astrazeneca, Beigene, Bio-Thera, Hikma, Henlius, Junshi, Liquidia, Moderna, Ocugen, Organon, Otsuka, Poolbeg, Remegen, Samsung Bioepsis, Savara, Traws.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Altamira, Ayrmid, Bioinvent, Biolinerx, Boundless Bio, Galmed, Hansa, Novartis, Rheacell, Regulus, Sanofi, Xoma.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Asklepios, Bayer, Bioxcel, Gilgamesh, Immutep, Innovent, Invivyd, Iolyx, Mineralys, Palisade, Rocket.

Biopharmas raising money in public or private financings, including: Algernon, Alligator, Imunon, ITM, Lexeo.

New hires and promotions in the biopharma industry, including: Indivior, Mind, Nucleome, Palvella, Storm, Vectory, Volastra.

The U.S. Trade Representative (USTR) is asking for help in its search for “freeloaders” that refuse to shoulder their share of the cost of biopharma R&D.

Glycoengineering specialist Glycoera AG is preparing to take its extracellular protein degrader constructs into the clinic in the treatment of autoimmune diseases, after closing a $130 million series B.

After reporting in April that its gastrointestinal reprogramming product (Garp) failed to meet the primary efficacy endpoint in a phase II trial in irritable bowel syndrome (IBS), Anatara Lifesciences Ltd. conducted a further analysis that shows a positive trend toward efficacy.